User profiles for Vicky Baillie
 | Vicky BaillieUniversity of the Witwatersrand and the Vaccine and Infectious Disease Analytics (VIDA) … Verified email at wits-vida.org Cited by 15565 |
Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant
Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim …
Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
…, A Pauvolid-Correa, MM Siqueira, V Baillie… - Cell, 2022 - cell.com
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
[HTML][HTML] Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a …
…, E Azziz-Baumgartner, HC Baggett, VL Baillie… - The Lancet, 2017 - thelancet.com
Background We have previously estimated that respiratory syncytial virus (RSV) was associated
with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in …
with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant
…, G Kruger, N Carrim-Ganey, V Baillie… - … England Journal of …, 2021 - Mass Medical Soc
Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study
…, TP Anderson, M Antonio, JO Awori, VL Baillie… - The Lancet, 2019 - thelancet.com
Background Pneumonia is the leading cause of death among children younger than 5 years.
In this study, we estimated causes of pneumonia in young African and Asian children, using …
In this study, we estimated causes of pneumonia in young African and Asian children, using …
Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis
…, GA Talavera, D Badarch, VL Baillie… - The Lancet Global …, 2019 - thelancet.com
Background Influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus
are the most common viruses associated with acute lower respiratory infections in …
are the most common viruses associated with acute lower respiratory infections in …
